Dr. John Cush RheumNow
2 years 10 months ago
Chemokine CXCL10 a potential biomarker for ILD in systemic sclerosis (SSc)? Study of 165 SSc pts (41 w/ SSc-ILD) found higher serum CXCL10 in SSc-ILD (126 vs. 78.5 pg/ml). Hi levels incr risk of ILD 2.74-fold. Most CXCL10 from inflammed lung tissues https://t.co/Z8pIAZYaC0 https://t.co/ErRsD9Msn1
Whether it’s RA, SLE or Sjogren’s, the increased prevalence of females affected by auto-immune diseases is well established, yet not fully understood. Often, I have heard that sexual hormones are responsible for every aspect of it. Two abstracts presented this year question this paradigm.
A lot of interesting studies will be presented at the poster sessions on Sunday, November 12 and some of them address practical real-world issues such as treatment intensification and the impact of pregnancy on axSpA imaging.
Dr. Jack Cush reviews this past week's news and journal reports from RheumNow.com. Good news is that nearly 99% of adult rheumatology positions matched! But the challenge is that 45% of pediatric fellowship programs and 39% of pediatric rheum slots were unfilled in the 2024 NRMP match.
Dr. John Cush RheumNow
2 years 10 months ago
Study from British Columbia, Canada, showed between 2010 & 2020, they saw 31% more new pt rheum consults (149,902); 1st time consults for inflammatory arthritis incr 28% to 51%. While time to 1st visit decr. 35%, time to DMARD initiation was unchanged https://t.co/Et7GzxKeNe https://t.co/2as2YuIV4d
Psoriatic arthritis and the gut microbiome have become more intertwined, especially in the past few years. It was to my amazement that one of the first abstracts I came across was the effect of probiotic modulation on gut dysbiosis and disease activity in psoriatic arthritis patients.
Dr. John Cush RheumNow
2 years 10 months ago
Watch: Effects of Apremilast on Cardiometabolic Effects in PsA
https://t.co/aKMxEfbc4c https://t.co/wjcEjLtlaC
While adult rheumatology programs continue to have high match rates, pediatric rheumatology programs remain less popular.The National Residency Matching Program announced yesterday that the 2024 rheumatology fellowship match filled 97.6% (124/127) of programs, and 98.9% (273/276) of rheumatology fellowship positions. This is on par with last years (2023) adult rheumatology match wherein 97.8% (265/271) of the rheumatology fellow positions were
The Lancet Rheumatology TheLancetRheum
2 years 10 months ago
NEW Health Policy—Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline https://t.co/WYNcVigb7n Free to read with registration on https://t.co/28wkm59DgB https://t.co/Qbm1y76o3E
Dr. John Cush RheumNow
2 years 10 months ago
Real World Experience with PEXIVAS Low Steroid Taper
Dr. Mike Putman discusses abstract 0725 with Dr. Sophie Nagle at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/lXTyb93ata https://t.co/kC6J9Zuurf
Dr. John Cush RheumNow
2 years 10 months ago
What do you think of the concept of "dysuricemia" - the concept that both hyperuricemia and hypouricemia influence diseases. “The lower, the better” is incorrect; the ideal is to maintain normouricemia, or optimal SU level, to reduce the urate burden https://t.co/Vi9htWTNwr https://t.co/fsx9Oq08Ak
Dr. John Cush RheumNow
2 years 10 months ago
Reconsidering Steroids
Not one of us in rheumatology hasn’t prescribed steroids, but we need to reconsider how much/how often we use them. In almost every disease state we treat, we are seeing progression towards lesser and shorter courses .
https://t.co/VRlCeNXyKR https://t.co/k5Uy7IHr3h
Dr. John Cush RheumNow
2 years 10 months ago
TNFi and RA-ILD – The Pendulum Swings Again
Tumour necrosis factor inhibitors (TNFi) revolutionised the treatment of rheumatoid arthritis. They heralded the wave of advanced therapies, which has transformed the treatment landscape in rheumatic disease.
https://t.co/zBwJKyDihL https://t.co/uCLnmaLC9j
Dr. John Cush RheumNow
2 years 10 months ago
Single center obs. study 74 RA-ILD pts Rx w/ antifibrotics (40 nintedanib; 34 pirfenidone); F/U 89 wks, had signif improvement in FVC estimated decline after antifibrotics (-0.3% w/ vs -6.2% w/o). 35% died, 4 lung transplants. 55% AEs, 46% D/C Rx https://t.co/s6O5uU3z2i

